RELMADA THERAPEUTICS, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
RELMADA THERAPEUTICS, INC. (RLMD) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $122.50 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-19
- RELMADA THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $122.50M, a 6.19% increase from fiscal 2024.
- RELMADA THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $115.36M, a 2109.10% increase from fiscal 2023.
- RELMADA THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $5.22M, a 74.15% decline from fiscal 2022.
- RELMADA THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $20.20M, a 55.87% decline from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 6 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 6 month as first filed | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|---|---|
| 2025-12-31 | $122.50M 10-K · filed 2026-03-19 | |||
| 2024-12-31 | $115.36M 10-K · filed 2026-03-19 | -$6.26M 10-K · filed 2025-03-27 | ||
| 2023-12-31 | $5.22M 10-K · filed 2025-03-27 | -$6.26M 10-K · filed 2024-03-19 | ||
| 2022-12-31 | $20.20M 10-K · filed 2024-03-19 | |||
| 2021-12-31 | $45.77M 10-K · filed 2023-03-23 | |||
| 2020-12-31 | $24.47M 10-K · filed 2022-03-25 | $2.66M 10-K · filed 2021-03-24 | ||
| 2019-12-31 | $4.36M 10-K · filed 2021-03-24 | $2.66M 10-KT · filed 2020-03-26 | ||
| 2019-06-30 | $24.47M 10-K · filed 2021-03-24 | $4.38M 10-K · filed 2019-09-24 | ||
| 2018-06-30 | -$235.00K 10-KT · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |